Wakunaga Pharmaceutical To Establish U.S. Factory To Produce Generics
This article was originally published in PharmAsia News
Osaka-based Wakunaga Pharmaceutical announced April 30 that it will spend ¥1.5 billion to build a factory in California to produce OTC drugs. Wakunaga's goal is to establish OTC production facilities in Japan, the U.S. and Europe. The construction will start in July and is estimated to be completed in November 2011. Wakunaga plans to produce over 100 products in the new facility. (Click here for more - Japanese language)
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.